港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

科倫博泰生物-B

301.600

+16.2005.68%

成交量：68.92萬

成交額：2.07億

市值：684.63億

市盈率：-236.15

高：308.600

開：280.000

低：278.000

收：285.400

資料載入中...

總覽公司新聞公告

科倫博泰生物-B盤中異動股價大跌5.06%報178.100港元

【券商聚焦】浦銀國際對2025年醫藥板塊整體呈樂觀態度看好創新藥、醫療器械及CXO

國金證券：醫藥政策暖風先到關注創新藥和仿創藥的板塊高景氣度投資機會

國信證券2025年醫藥生物策略：創新引領產業升級

科倫博泰生物-B盤中漲超5% 天風證券首次覆蓋給予“增持”評級

港股異動 | 科倫博泰生物-B(06990)漲超5% ADC自研能力突出多款產品即將進入商業化階段

異動解讀 | 科倫博泰生物-B旗艦產品SKB264國內上市獲批,多款在研管線推進,公司股價盤中大漲5.43%

科倫博泰生物-B盤中異動快速拉昇5.43%報194.200港元

天風證券：首予科倫博泰生物-B(06990)“增持”評級商業化確定性加強

科倫博泰生物-B(06990)：鍾明輝已獲委任為聯席公司秘書

中銀國際：25年醫療設備採購需求有望逐步釋放創新藥仍是醫藥生物重點

科倫博泰生物-B獲批SKB500臨牀試驗研發前景存不確定性

科倫博泰生物-B(06990)：SKB500新藥臨牀試驗申請獲國家藥品監督管理局批准

科倫博泰生物(06990.HK)創新藥SKB500獲國家藥監局批准新藥臨牀試驗

阿斯达克财经

科倫博泰生物：蘆康沙妥珠單抗獲批上市上調目標價至 230 港元

《大行》中金升科倫博泰生物(06990.HK)目標價至230元 TROP2 ADC獲批上市期待商業化放量

阿斯达克财经

中金：維持科倫博泰生物-B(06990)“跑贏行業”評級目標價上調至230港元

異動解讀 | 科倫博泰生物-B股價盤中大漲5.24% 年報數據向好預期釋放利好

【券商聚焦】招銀國際：多款重磅國產創新藥納入醫保基金收支有望改善

《大行》里昂升科倫博泰生物(06990.HK)目標價至236.6元治療癌症藥物獲批上市

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/06990/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科倫博泰生物-B","latestPrice":301.6,"timestamp":1745294700006,"preClose":285.4,"halted":0,"volume":689200,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.277171199810687,"marketStatus":"午間休市","change":16.2,"latestTime":"04-22 12:05:00","open":280,"high":308.6,"low":278,"amount":207368765,"amplitude":0.107218,"askPrice":302.6,"askSize":400,"bidPrice":301.4,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.277171199810687,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1745298000000},"marketStatusCode":3,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":285.4,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":1.905366,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.277171,"volumeRatio":1.905366,"shares":227000000,"dividePrice":0,"high":308.6,"amplitude":0.107218,"preClose":285.4,"low":278,"week52Low":120.2,"pbRate":"19.50","psRate":"33.38","week52High":346,"institutionHeld":0,"latestPrice":301.6,"committee":-0.333333,"eps":-1.277171199810687,"divideRate":0,"volume":689200,"delay":0,"ttmEps":-1.277171199810687,"open":280,"prevYearClose":163.3,"prevWeekClose":285.4,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":302,"twentyDayClose":264.2,"sixtyDayClose":167.7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2491818196","title":"科倫博泰生物-B盤中異動 股價大跌5.06%報178.100港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2491818196","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491818196?lang=zh_tw&edition=fundamental","pubTime":"2024-12-16 09:59","pubTimestamp":1734314346,"startTime":"0","endTime":"0","summary":"2024年12月16日早盘09时59分，科伦博泰生物-B股票出现异动，股价快速下跌5.06%。截至发稿，该股报178.100港元/股，成交量3.73万股，换手率0.03%，振幅4.90%。资金方面，该股资金流入189.058万港元，流出446.681万港元。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为0.64%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121609590695e9f880&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121609590695e9f880&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2490879827","title":"【券商聚焦】浦銀國際對2025年醫藥板塊整體呈樂觀態度 看好創新藥、醫療器械及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879827","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490879827?lang=zh_tw&edition=fundamental","pubTime":"2024-12-12 15:52","pubTimestamp":1733989962,"startTime":"0","endTime":"0","summary":"2)医疗器械：看好创新高值耗材、医疗设备板块。康诺亚核心产品CM310将于2025年迎来首个完整年度商业化，作为首个国产重磅IL4R，该行认为其市场潜力巨大。此外，康诺亚研发实力强劲，NewCo形式有助于加快其出海步伐，2025年潜在出海交易有望进一步提振股票行情。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1949533","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426308.USD","BK1589","BK1141","09939","BK1100","06160","02359","159992","LU2328871848.SGD","02269","00013","LU2125910500.SGD","LU0348784397.USD","LU2045819591.USD","LU1720050803.USD","LU0181495838.USD","BK1610","01789","BK1191","02190","LU0043850808.USD","LU0516422366.SGD","LU0359202008.SGD","09926","IE00B5MMRT66.SGD","IE00B543WZ88.USD","09996","LU2488822045.USD","LU0979878070.USD","LU0327786744.USD","LU0348735423.USD","LU0572944931.SGD","CXO","02162","02268","SG9999014674.SGD","03759","159883","06990","LU0196878994.USD","SG9999002463.SGD","LU0856984785.SGD","LU0307460666.USD","159938","LU0417516738.SGD","06978","LU0819121731.USD","SG9999002562.SGD","BK1521","09997"],"gpt_icon":1},{"id":"2490710267","title":"國金證券：醫藥政策暖風先到 關注創新藥和仿創藥的板塊高景氣度投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2490710267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490710267?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 16:14","pubTimestamp":1733732057,"startTime":"0","endTime":"0","summary":"2024年医药承压持续探底，但长期需求稳定，且政策、资金、基本面都存在反转趋势，2025年医药赛道有望取得超额收益，医药板块核心投资机会将围绕三大逻辑：1)创新出海；2)需求复苏；3)政策预期反转，关注创新药和仿创药的板块高景气度投资机会。投资建议2025年医药板块最大投资机会将围绕于两条主线：创新药和仿创药的板块高景气度投资机会；以及器械、中药、药店、消费医疗服务等领域的个股见底反弹投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0012","BK0183","BK0188","BK1161","09939","LU0196878994.USD","BK0276","159938","BK0028","BK0201","06990","600109","159992","BK1515","BK1574"],"gpt_icon":0},{"id":"2490719420","title":"國信證券2025年醫藥生物策略：創新引領 產業升級","url":"https://stock-news.laohu8.com/highlight/detail?id=2490719420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490719420?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 14:47","pubTimestamp":1733726829,"startTime":"0","endTime":"0","summary":"国信证券主要观点如下：需求端：医药行业需求增长稳定，且呈现需求升级的趋势。国信证券认为，展望2025年，当前国内医疗需求持续升级，宏观经济有望逐步回暖，在地缘政治扰动之下，国家有望加大对于自主可控的支持力度，建议优先配置创新药、创新器械、医疗设备等细分行业，同时建议关注AI医疗、并购重组等带来的主题投资机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","LU0196878994.USD","002736","BK1191","LU1794554557.SGD","000808.SH","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0348783233.USD","BK1588","00013","09926","BK1161","BK0188","BK0276","BK0183","LU0417516571.SGD","163118","LU1720050803.USD","BK0028","BK1587","06990","LU0348784397.USD"],"gpt_icon":0},{"id":"2490791161","title":"科倫博泰生物-B盤中漲超5% 天風證券首次覆蓋給予“增持”評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2490791161","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490791161?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 11:55","pubTimestamp":1733716500,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　科伦博泰生物-B（06990）盘中曾涨超5%，截至发稿，股价上涨2.33%，现报188.50港元，成交额1.01亿港元。\n　　天风证券发布研究报告称，首次覆盖科伦博泰生物-B（06990），给予以“增持”评级，预计公司2024-2026年营业收入分别为12.17亿元、16.54亿元和24.76亿元；归母净利润分别为-7.20亿元、-6.06亿元、-4.15亿元。考虑到公司ADC技术平台优势突出，核心品种市场空间大，出海前景较好，看好公司发展。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-09/doc-incyvtfr2851912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06990","601162"],"gpt_icon":0},{"id":"2490798267","title":"港股異動 | 科倫博泰生物-B(06990)漲超5% ADC自研能力突出 多款產品即將進入商業化階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2490798267","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490798267?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 10:18","pubTimestamp":1733710738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B涨超5%，截至发稿，涨5.27%，报193.5港元，成交额5210.24万港元。天风证券发布研报称，科伦博泰拥有自主知识产权的ADC研发平台OptiDC，具备从研发到生产的全流程开发体系。截至2024年6月，公司共有5款ADC处于临床开发阶段，其中A166和SKB264 已经进入NDA阶段，SKB315 、SKB410和SKB518处于临床Ⅰ期阶段，多款产品处于临床前研究阶段。公司的ADC研发能力深受国际巨头默沙东认可，就SKB264以及其他在研品种达成多项合作，共计合作款项约118亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK4080","BK1161","ADC","LU0196878994.USD","BK4231"],"gpt_icon":0},{"id":"1196902500","title":"異動解讀 | 科倫博泰生物-B旗艦產品SKB264國內上市獲批,多款在研管線推進,公司股價盤中大漲5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196902500","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196902500?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 10:12","pubTimestamp":1733710346,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B今日盘中股价大涨5.43%,引发市场广泛关注。消息面上,公司旗舰产品SKB264近期在国内正式获批上市,标志着公司核心产品正式进入商业化阶段。分析人士指出,作为国产进度第一、全球进度前三的TROP2 ADC药物,SKB264疗效突出,有效缓解多种恶性肿瘤患者症状,未来市场空间广阔。除SKB264外,科伦博泰生物-B在研管线丰富,包括PD-L1单抗A167、HER2 ADC A166等多款产品已申报新药上市,有望于未来陆续获批上市。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科伦博泰生物-B旗舰产品SKB264国内上市获批,多款在研管线推进,公司股价盘中大涨5.43%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2490798216","title":"科倫博泰生物-B盤中異動 快速拉昇5.43%報194.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490798216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490798216?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 10:11","pubTimestamp":1733710279,"startTime":"0","endTime":"0","summary":"2024年12月09日早盘10时11分，科伦博泰生物-B股票出现异动，股价快速拉升5.43%。截至发稿，该股报194.200港元/股，成交量24.53万股，换手率0.19%，振幅6.73%。科伦博泰生物-B股票所在的生物技术行业中，整体涨幅为0.86%。该信息摘要如下：天风证券发布研究报告称，首次覆盖科伦博泰生物-B，予以“增持”评级，预计公司2024-2026年营业收入分别为12.17亿元、16.54亿元和24.76亿元;归母净利润分别为-7.20亿元、-6.06亿元、-4.15亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209101120971caa1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209101120971caa1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2490076068","title":"天風證券：首予科倫博泰生物-B(06990)“增持”評級 商業化確定性加強","url":"https://stock-news.laohu8.com/highlight/detail?id=2490076068","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490076068?lang=zh_tw&edition=fundamental","pubTime":"2024-12-09 09:50","pubTimestamp":1733709026,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，天风证券发布研究报告称，首次覆盖科伦博泰生物-B，予以“增持”评级，预计公司2024-2026年营业收入分别为12.17亿元、16.54亿元和24.76亿元;归母净利润分别为-7.20亿元、-6.06亿元、-4.15亿元。天风证券主要观点如下：ADC自研能力突出，全球研发由默沙东推进，商业化确定性加强科伦博泰拥有自主知识产权的ADC研发平台OptiDC，具备从研发到生产的全流程开发体系。近期SKB264在国内获批上市，正式迈入商业化阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","601162"],"gpt_icon":0},{"id":"2489740299","title":"科倫博泰生物-B(06990)：鍾明輝已獲委任為聯席公司秘書","url":"https://stock-news.laohu8.com/highlight/detail?id=2489740299","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489740299?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 18:19","pubTimestamp":1733480348,"startTime":"0","endTime":"0","summary":"冯慧森辞任后，董事会欣然宣布，钟明辉已获公司委任为联席公司秘书、授权代表及根据公司条例第16部项下及上市规则第19A.13项下的法律程序文件代理人，以接替冯慧森的空缺，自2025年1月1日起生效。周泽剑将继续担任另一名联席公司秘书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2489775674","title":"中銀國際：25年醫療設備採購需求有望逐步釋放 創新藥仍是醫藥生物重點","url":"https://stock-news.laohu8.com/highlight/detail?id=2489775674","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489775674?lang=zh_tw&edition=fundamental","pubTime":"2024-12-06 15:21","pubTimestamp":1733469664,"startTime":"0","endTime":"0","summary":"同时，伴随资金面因素的回暖，CXO和科研服务的需求及医疗设备采购有望逐步恢复。此外，创新仍然是医药生物板块中值得关注的点，有望给企业带来新的增量。但是，一方面，随着地方财政化债等增量政策出台，医院资金压力有望进一步缓解，另一方面，目前部分地区已经公布了更新方案和投资规模，随着具体更新方案的实施，预期2024年上半年推迟的医疗设备采购需求有望在2025年逐步释放。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","BK1100","LU0348784397.USD","BK1574","IE00BPRC5H50.USD","LU1969619763.USD","BK1585","06990","BK1161","IE00B543WZ88.USD","LU0196878994.USD","LU0417516571.SGD","159992","LU1794554557.SGD","LU2488822045.USD","LU1720050803.USD","LU0348783233.USD","000808.SH","01801","159873","06978","IE00B5MMRT66.SGD","163118","LU2328871848.SGD","BK1589","01789","BK1583"],"gpt_icon":0},{"id":"2488502199","title":"科倫博泰生物-B獲批SKB500臨牀試驗 研發前景存不確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2488502199","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488502199?lang=zh_tw&edition=fundamental","pubTime":"2024-12-04 21:14","pubTimestamp":1733318077,"startTime":"0","endTime":"0","summary":"财中社12月4日电科伦博泰生物-B（06990）发布公告称，公司于2024年12月4日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB500新药临床试验申请的临床试验通知书。SKB500是一款由公司利用OptiDCTM平台技术研发的新型ADC药物，具有自主知识产权，主要用于治疗晚期实体瘤。在临床前研究中，SKB500显示出良好的疗效和安全窗。公告中提到，尽管获得了临床试验批准，但SKB500最终能否成功开发及商业化仍存在不确定性。文章来源：财中社原标题：科伦博泰生物-B获批SKB500临床试验 研发前景存不确定性","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204214648a26c47f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204214648a26c47f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","BK1576","BK1583","03347","BK1161","06990","BK1141"],"gpt_icon":0},{"id":"2488151880","title":"科倫博泰生物-B(06990)：SKB500新藥臨牀試驗申請獲國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2488151880","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488151880?lang=zh_tw&edition=fundamental","pubTime":"2024-12-04 16:45","pubTimestamp":1733301914,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已于2024年12月4日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB500新药临床试验申请的临床试验通知书。SKB500是一款由公司针对靶点生物学特点，利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物，在临床前研究中显示出良好的疗效和安全窗，拟用于治疗晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1141","LU0196878994.USD","BK1583","BK1576","06990","BK1161"],"gpt_icon":0},{"id":"2488151102","title":"科倫博泰生物(06990.HK)創新藥SKB500獲國家藥監局批准新藥臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2488151102","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488151102?lang=zh_tw&edition=fundamental","pubTime":"2024-12-04 16:45","pubTimestamp":1733301900,"startTime":"0","endTime":"0","summary":"科伦博泰生物(06990.HK) 公布，已于12月4日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB500新药临床试验申请的临床试验通知书。SKB500是一款由公司针对靶点生物学特点，利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物，在临床前研究中显示出良好的疗效和安全窗，拟用于治疗晚期实体瘤。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-04 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401781/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03347","BK1141","159992","LU0196878994.USD","BK1161","06978","06990","BK1576","BK1583","BK1574"],"gpt_icon":0},{"id":"2488137913","title":"科倫博泰生物：蘆康沙妥珠單抗獲批上市 上調目標價至 230 港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488137913","media":"和讯网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488137913?lang=zh_tw&edition=fundamental","pubTime":"2024-12-04 14:21","pubTimestamp":1733293305,"startTime":"0","endTime":"0","summary":"中金发表报告称，本次批准基于国内三期临床试验 OptiTROP-Breast01 的积极结果。中金因芦康沙妥珠单抗获批上市调整风险因子，考虑到商业化节奏良好，基本维持 2024 年收入预测 17.1 亿元不变，上调 2025 年收入预测 11.1%至 11.4 亿元；考虑到研发费用节奏，基本维持 2024 年和 2025 年净利润预测亏损 4.9 亿元和亏损 12.9 亿元不变。该行维持对其“跑赢行业”评级，上调目标价 9.5%至 230 港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204145950a26b6efc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204145950a26b6efc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990"],"gpt_icon":0},{"id":"2488136630","title":"《大行》中金升科倫博泰生物(06990.HK)目標價至230元 TROP2 ADC獲批上市期待商業化放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2488136630","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488136630?lang=zh_tw&edition=fundamental","pubTime":"2024-12-04 13:39","pubTimestamp":1733290740,"startTime":"0","endTime":"0","summary":"中金发表报告，科伦博泰生物公告核心产品芦康沙妥珠单抗在中国获批上市，用于治疗2L及以上三阴性乳腺癌，这是国内首个获批上市的国产TROP2 ADC。该行认为芦康沙妥珠单抗的临床数据具有竞争力，为国内患者带来新的治疗选择。维持“跑赢行业”评级，上调目标价9.5%至230港元。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401713/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2488895311","title":"中金：維持科倫博泰生物-B(06990)“跑贏行業”評級 目標價上調至230港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488895311","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488895311?lang=zh_tw&edition=fundamental","pubTime":"2024-12-04 10:35","pubTimestamp":1733279747,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研究报告称，维持科伦博泰生物-B(06990)“跑赢行业”评级，上调集团目标价9.5%至230港元。集团另有“芦康沙妥珠单抗单”药治疗EGFR-TKI经治（2L）及EGFR-TKI及含铂化疗经治（3L）的非小细胞肺癌（NSCLC）上市申请，已获国家药监局受理，该行预计有望在2025年获批上市。报告中称，由于科伦博泰生物核心产品“芦康沙妥珠单抗”(sac-TMT)获批上市，该行认为，该产品的临床数据具有竞争力，或为内地患者带来新的治疗选择。同时调整风险因子及考虑到商业化节奏良好，上调集团明年收入预测11.1%至11.4亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990"],"gpt_icon":0},{"id":"1174732799","title":"異動解讀 | 科倫博泰生物-B股價盤中大漲5.24% 年報數據向好預期釋放利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1174732799","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174732799?lang=zh_tw&edition=fundamental","pubTime":"2024-12-03 17:25","pubTimestamp":1733217943,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990)今日盘中大涨5.24%,引起市场关注。根据财报数据,公司实现营业收入15.15亿港元,净利润3.40亿港元,每股收益1.54港元,毛利11.80亿港元,显示业绩数据向好。\n此外,公司所处生物技术行业整体上涨0.47%,表现相对向好。机构方面,目前全部12家分析机构均给予买入评级,没有持有或卖出评级,反映外部看好公司长期发展预期。\n综合来看,市场对科伦博泰生物-B的盈利能力和增长前景抱有较高预期,年报数据向好加上外部看好评级预计是今日股价大涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科伦博泰生物-B股价盘中大涨5.24% 年报数据向好预期释放利好","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2488962929","title":"【券商聚焦】招銀國際：多款重磅國產創新藥納入醫保 基金收支有望改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2488962929","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488962929?lang=zh_tw&edition=fundamental","pubTime":"2024-12-03 17:22","pubTimestamp":1733217761,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际发研指，MSCI中国医疗指数年初至今累计下跌17.6%，跑输MSCI中国指数30.1%。新版医保目录已公布，多款重磅国产创新药纳入，该行预期续约品种价格降幅较温和，体现医保基金持续大力支持创新药。今年9、10月份，基本医疗保险的收支结余显著改善。随着政策焦点转向刺激经济，该行认为医保基金收支状况有望大幅改善。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1948888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","06990","06978","06160","01530","BK1588","BK1593","LU2125910500.SGD","BK1583","LU2328871848.SGD","BK1576","LU0708995583.HKD","LU2045819591.USD","BK1161","LU0052750758.USD","BK1589","159992","LU0320764599.SGD","LU2488822045.USD","BK1141","01801","LU0307460666.USD","LU1046422090.SGD","LU0196878994.USD","LU0588546209.SGD","LU2242644610.SGD","BK1500","LU1969619763.USD","02367","BK1207","BK1574"],"gpt_icon":0},{"id":"2488960497","title":"《大行》里昂升科倫博泰生物(06990.HK)目標價至236.6元  治療癌症藥物獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2488960497","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488960497?lang=zh_tw&edition=fundamental","pubTime":"2024-12-03 15:55","pubTimestamp":1733212500,"startTime":"0","endTime":"0","summary":"里昂发表研究报告指，科伦博泰生物宣布旗下抗体药物偶联物芦康沙妥珠单抗获国家药品监督管理局批准于中国上市，用于治疗至少接受过2种系统治疗、不可切除的局部晚期或转移性三阴性乳腺癌成人患者，获批时间符合该行及公司预期。该行亦相应地将科伦博泰生物的目标价上调至236.6元，重申“跑赢大市”评级。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161536655_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1401446/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盤後","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盤後","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744819200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745295485446}}}